Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 9102 results

  1. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  2. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  4. Staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-HTG10860 Expected publication date:  17 December 2026

    HealthTech guidance
    In development

  5. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pritelivir (AIC-316) for Herpes simplex virus 2 infection (HSV-2) [12367]

    Awaiting development Reference number: GID-TA12465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  8. Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  10. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Aprocitentan for treating resistant hypertension [ID6681]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]

    Technology appraisal Reference number: TA714 Published:  14 July 2021

    Technology appraisal guidance
    In development

  14. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  15. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development